From Nanotech to PEGylation: Drug Delivery Is Revolutionizing Patient Care

A Revolution in Drug Discovery: Past, Present, and Future

The pharmaceutical industry has continuously evolved to improve how medications are delivered, especially for managing chronic diseases. Early innovations like sustained-release capsules (introduced in the 1950s) and long-acting injectables (1980s) laid the groundwork for today’s more advanced solutions. But as chronic and life-threatening diseases became more prevalent, it became clear that traditional methods weren’t enough. 

By the early 2000s, advances in nanotechnology and PEGylation began to revolutionize drug delivery. The National Nanotechnology Initiative marked a turning point, enabling precise manipulation of materials at the atomic level. Around the same time, PEGylation—attaching polyethylene glycol (PEG) to drugs—extended drug stability and circulation, leading to groundbreaking therapies like Doxil®. While not a perfect solution for targeted delivery, Doxil® demonstrated how liposome-based cancer treatments could reduce side effects and improve outcomes for patients.

Breaking Through Biological Barriers  

Despite these advances, many drugs still face significant hurdles. Poor water solubility limits effectiveness, while biological barriers prevent others from reaching their targets. These challenges can lead to reduced efficacy and increased side effects for patients.

The industry has responded with solutions like drug-polymer complexes (e.g., InFed®) to enhance solubility and antibody-drug conjugates (ADCs) to improve targeting. Mylotarg™, the first ADC approved for leukemia, uses monoclonal antibodies to deliver potent drugs directly to cancer cells, sparing healthy tissue. ADCs represent a significant step forward, though their development is part of a broader push to refine targeted therapies.

Nanotechnology: Progress and Promise in Drug Delivery

Nanotechnology has redefined drug delivery, unlocking exciting possibilities even as some early ambitions remain unmet. When it first emerged, nanomedicine was seen as a game-changer for cancer treatment, with the goal of delivering drugs directly to tumors using the enhanced permeability and retention (EPR) effect. While this sounded like a silver bullet, the reality has been more nuanced. A handful of formulations, like Doxil® and Abraxane®, have succeeded—not by drastically improving efficacy but by reducing side effects, which is still a big win for patients.

The real breakthroughs have come in unexpected areas. By creating nanosized drug crystals, researchers have improved the solubility and stability of drugs that otherwise struggle in the body’s watery environment. Rapamune®, the first FDA-approved nanocrystal formulation, is a great example. Meanwhile, lipid nanoparticles have been a game-changer for modern therapies, most notably in the development of COVID-19 mRNA vaccines. These innovations show how nanotech can enhance drug delivery and formulation, making treatments more effective and accessible.

While we’re not quite at the point of precision-targeted cancer nanomedicine, the progress so far has been impressive—and it’s clear that this field has plenty more to offer.

PEGylation: Enhancing Drug Stability and Delivery  

PEGylation, the attachment of polyethylene glycol (PEG) to drugs, has become a cornerstone of modern drug delivery, extending circulation time and reducing immune system interference. This technology has been pivotal in advancing therapies like mRNA-based COVID-19 vaccines, where PEGylated lipid nanoparticles ensure safe and effective delivery.

While PEGylation poses challenges like anti-PEG antibody formation, its benefits often outweigh these limitations, enabling therapies that are more effective and patient-friendly. This technology continues to pave the way for treatments that combine longevity with reduced side effects, improving the quality of life for patients.

Beyond stability, PEGylation has driven innovations like Doxil®, a cancer therapy with reduced toxicity, and Movantik®, which limits blood-brain barrier transport to minimize side effects. Its versatility continues to open doors for safer, longer-lasting treatments across various fields.

What’s Next for Drug Delivery Systems?  

Drug delivery systems have made impressive strides, but challenges remain. Developers are refining methods to improve stability, reduce toxicity, and enhance targeting. Two key approaches—drug-polymer complexes and drug-polymer conjugates—are central to these efforts.

Drug-polymer complexes, such as those in InFed® and Abraxane®, improve solubility by using water-soluble polymers. Drug-polymer conjugates go a step further by covalently bonding drugs to polymer carriers, enabling higher drug loading and the addition of targeting moieties or imaging agents. However, early trials revealed that targeting moieties alone often fall short—drug distribution still relies heavily on circulation, and targeted interactions typically occur too late to be fully effective.

To dive deeper into the cutting-edge strategies driving advancements in drug delivery and beyond, explore our brand new eBook Unlocking Undruggable Targets, Vol. 2. This comprehensive eBook uncovers the latest breakthroughs in overcoming biological barriers and developing therapies for previously unreachable targets. Download your free copy today!

Stay informed by signing up for our newsletter, where you'll gain early access to the latest insights, trends, and breakthroughs in drug discovery, powered by cutting-edge data and analysis from industry-leading experts.